About Cytek Biosciences
Cytek Biosciences is a company based in San Francisco (United States) founded in 2014.. Cytek Biosciences has raised $132 million across 3 funding rounds from investors including Orbimed, RA Capital and NLVC. The company has 648 employees as of December 31, 2024. Cytek Biosciences operates in a competitive market with competitors including Accuri Cytometers, ACEA Biosciences, Bioaffinity technologies, Orflo and NanoFCM, among others.
- Headquarter San Francisco, United States
- Employees 648 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Cytek Biosciences, Inc.
-
Annual Revenue
$200.45 M3.85as on Dec 31, 2024
-
Net Profit
$-6.02 M50.44as on Dec 31, 2024
-
EBITDA
$-12.63 M26.19as on Dec 31, 2024
-
Total Equity Funding
$132 M (USD)
in 3 rounds
-
Latest Funding Round
$120 M (USD), Series D
Nov 05, 2020
-
Investors
Orbimed
& 5 more
-
Employee Count
648
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Cytek Biosciences
Cytek Biosciences is a publicly listed company on the NASDAQ with ticker symbol CTKB in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Unlock access to complete
Funding Insights of Cytek Biosciences
Cytek Biosciences has successfully raised a total of $132M across 3 strategic funding rounds. The most recent funding activity was a Series D round of $120 million completed in November 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series D — $120.0M
-
First Round
First Round
(25 Jan 2017)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2020 | Amount | Series D - Cytek Biosciences | Valuation | RA Capital Management , Hillhouse | |
| Sep, 2018 | Amount | Series C - Cytek Biosciences | Valuation | Northern Light Venture Capital , 3E BioVentures |
|
| Jan, 2017 | Amount | Series B - Cytek Biosciences | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Cytek Biosciences
Cytek Biosciences has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, RA Capital and NLVC. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Provider of early stage venture capital focused on technology companies
|
Founded Year | Domain | Location | |
|
A fund focused on healthcare industry investments is managed.
|
Founded Year | Domain | Location | |
|
Global private equity investments are managed with long-term focus.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Cytek Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Cytek Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cytek Biosciences Comparisons
Competitors of Cytek Biosciences
Cytek Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Accuri Cytometers, ACEA Biosciences, Bioaffinity technologies, Orflo and NanoFCM, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Compact flow cytometers for cell analysis are developed and provided.
|
|
| domain | founded_year | HQ Location |
Instruments for life science research are developed and marketed.
|
|
| domain | founded_year | HQ Location |
IVD platforms are developed to detect and target cancer cells.
|
|
| domain | founded_year | HQ Location |
Instrumentation for cell and protein analysis is developed and marketed.
|
|
| domain | founded_year | HQ Location |
Offers advanced tools for nanoparticle analysis in biotechnology and healthcare.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cytek Biosciences
Frequently Asked Questions about Cytek Biosciences
When was Cytek Biosciences founded?
Cytek Biosciences was founded in 2014 and raised its 1st funding round 3 years after it was founded.
Where is Cytek Biosciences located?
Cytek Biosciences is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is Cytek Biosciences a funded company?
Cytek Biosciences is a funded company, having raised a total of $132M across 3 funding rounds to date. The company's 1st funding round was a Series B of $12M, raised on Jan 25, 2017.
How many employees does Cytek Biosciences have?
As of Dec 31, 2024, the latest employee count at Cytek Biosciences is 648.
What is the annual revenue of Cytek Biosciences?
Annual revenue of Cytek Biosciences is $200.45M as on Dec 31, 2024.
What does Cytek Biosciences do?
Cytek Biosciences was founded in 2014 and is headquartered in San Francisco, United States. Operations focus on the development and production of flow cytometry systems within the biotechnology sector. The DxP Athena flow cytometer, a key product, is designed for 6 to 13 color detection using three lasers. Additional features include liquid handling for automated micro-sampling and integrated fluid management. These systems support research applications in life sciences.
Who are the top competitors of Cytek Biosciences?
Cytek Biosciences's top competitors include Bioaffinity technologies, Accuri Cytometers and ACEA Biosciences.
Is Cytek Biosciences publicly traded?
Yes, Cytek Biosciences is publicly traded on NASDAQ under the ticker symbol CTKB.
Who are Cytek Biosciences's investors?
Cytek Biosciences has 6 investors. Key investors include Orbimed, RA Capital, NLVC, 3E Bioventures, and Hillhouse.
What is Cytek Biosciences's ticker symbol?
The ticker symbol of Cytek Biosciences is CTKB on NASDAQ.